{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T09:37:23Z","timestamp":1769938643427,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41401-021-00775-5","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T08:02:48Z","timestamp":1638172968000},"page":"1843-1856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice"],"prefix":"10.1038","volume":"43","author":[{"given":"Qiu-ju","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-chao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-rong","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-lan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-jing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-hua","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-xiao","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-feng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-qiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-lin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"775_CR1","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1021\/jm3017706","volume":"56","author":"Y Wang","year":"2013","unstructured":"Wang Y, Kaiser CE, Frett B, Li HY. Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J Med Chem. 2013;56:5219\u201330.","journal-title":"J Med Chem"},{"key":"775_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nchembio.2264","volume":"13","author":"M Holderfield","year":"2016","unstructured":"Holderfield M, Morrison DK. RAS signaling: divide and conquer. Nat Chem Biol. 2016;13:7\u20138.","journal-title":"Nat Chem Biol"},{"key":"775_CR3","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/nm.2941","volume":"18","author":"LN Kwong","year":"2012","unstructured":"Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012;18:1503\u201310.","journal-title":"Nat Med"},{"key":"775_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/520278a","volume":"520","author":"H Ledford","year":"2015","unstructured":"Ledford H. Cancer: the Ras renaissance. Nature. 2015;520:278\u201380.","journal-title":"Nature"},{"key":"775_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s10637-012-9818-6","volume":"30","author":"D Laheru","year":"2012","unstructured":"Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, et al. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest N Drugs. 2012;30:2391\u20139.","journal-title":"Invest N Drugs"},{"key":"775_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/01.cad.0000185184.64980.39","volume":"17","author":"RJ Santen","year":"2006","unstructured":"Santen RJ, Lynch AR, Neal LR, McPherson RA, Yue W. Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells. Anticancer Drugs. 2006;17:33\u201340.","journal-title":"Anticancer Drugs"},{"key":"775_CR7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-06-0706","volume":"6","author":"A Zundelevich","year":"2007","unstructured":"Zundelevich A, Elad-Sfadia G, Haklai R, Kloog Y. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther. 2007;6:1765\u201373.","journal-title":"Mol Cancer Ther"},{"key":"775_CR8","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2217\/fon.10.71","volume":"6","author":"E Bustinza-Linares","year":"2010","unstructured":"Bustinza-Linares E, Kurzrock R, Tsimberidou AM. Salirasib in the treatment of pancreatic cancer. Future Oncol. 2010;6:885\u201391.","journal-title":"Future Oncol"},{"key":"775_CR9","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/ijc.21222","volume":"117","author":"W Yue","year":"2005","unstructured":"Yue W, Wang J, Li Y, Fan P, Santen RJ. Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. Int J Cancer. 2005;117:746\u201354.","journal-title":"Int J Cancer"},{"key":"775_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.clml.2015.02.018","volume":"15","author":"T Badar","year":"2015","unstructured":"Badar T, Cortes JE, Ravandi F, O\u2019Brien S, Verstovsek S, Garcia-Manero G, et al. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2015;15:433\u2013438.e2.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"775_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00280-018-3618-4","volume":"82","author":"J Furuse","year":"2018","unstructured":"Furuse J, Kurata T, Okano N, Fujisaka Y, Naruge D, Shimizu T, et al. An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed\/refractory solid tumors. Cancer Chemother Pharmacol. 2018;82:511\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"775_CR12","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/JTO.0b013e318223c099","volume":"6","author":"GJ Riely","year":"2011","unstructured":"Riely GJ, Johnson ML, Medina C, Rizvi NA, Miller VA, Kris MG, et al. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. J Thorac Oncol. 2011;6:1435\u20137.","journal-title":"J Thorac Oncol"},{"key":"775_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00280-009-1027-4","volume":"65","author":"AM Tsimberidou","year":"2010","unstructured":"Tsimberidou AM, Rudek MA, Hong D, Ng CS, Blair J, Goldsweig H, et al. Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol. 2010;65:235\u201341.","journal-title":"Cancer Chemother Pharmacol"},{"key":"775_CR14","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.juro.2012.09.056","volume":"189","author":"X Yang","year":"2013","unstructured":"Yang X, Shao C, Wang R, Chu CY, Hu P, Master V, et al. Optical imaging of kidney cancer with novel near infrared heptamethine carbocyanine fluorescent dyes. J Urol. 2013;189:702\u201310.","journal-title":"J Urol"},{"key":"775_CR15","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.2147\/IJN.S60206","volume":"9","author":"X Yi","year":"2014","unstructured":"Yi X, Wang F, Qin W, Yang X, Yuan J. Near-infrared fluorescent probes in cancer imaging and therapy: an emerging field. Int J Nanomed. 2014;9:1347\u201365.","journal-title":"Int J Nanomed"},{"key":"775_CR16","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1158\/1078-0432.CCR-10-0059","volume":"16","author":"X Yang","year":"2010","unstructured":"Yang X, Shi C, Tong R, Qian W, Zhau HE, Wang R, et al. Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res. 2010;16:2833\u201344.","journal-title":"Clin Cancer Res"},{"key":"775_CR17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.7150\/thno.5922","volume":"3","author":"NS James","year":"2013","unstructured":"James NS, Chen Y, Joshi P, Ohulchanskyy TY, Ethirajan M, Henary M, et al. Evaluation of polymethine dyes as potential probes for near infrared fluorescence imaging of tumors: part - 1. Theranostics. 2013;3:692\u2013702.","journal-title":"Theranostics"},{"key":"775_CR18","first-page":"2353","volume":"12","author":"L Duan","year":"2019","unstructured":"Duan L, Wang L, Zhang C, Yu L, Guo F, Sun Z, et al. Role of near-infrared heptamethine cyanine dye IR-783 in diagnosis of cervical cancer and its mechanism. Int J Clin Exp Pathol. 2019;12:2353\u201362.","journal-title":"Int J Clin Exp Pathol"},{"key":"775_CR19","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.3390\/molecules24224120","volume":"24","author":"Y Guan","year":"2019","unstructured":"Guan Y, Zhang Y, Zou J, Huang LP, Chordia MD, Yue W, et al. Synthesis and biological evaluation of genistein-IR783 conjugate: cancer cell targeted delivery in MCF-7 for superior anti-cancer therapy. Molecules. 2019;24:4120.","journal-title":"Molecules"},{"key":"775_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.biomaterials.2015.11.061","volume":"79","author":"B Zhang","year":"2016","unstructured":"Zhang B, Wang H, Shen S, She X, Shi W, Chen J, et al. Fibrin-targeting peptide CREKA-conjugated multi-walled carbon nanotubes for self-amplified photothermal therapy of tumor. Biomaterials. 2016;79:46\u201355.","journal-title":"Biomaterials"},{"key":"775_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11040","volume":"7","author":"H Almqvist","year":"2016","unstructured":"Almqvist H, Axelsson H, Jafari R, Dan C, Mateus A, Haraldsson M, et al. CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil. Nat Commun. 2016;7:11040.","journal-title":"Nat Commun"},{"key":"775_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1233606","volume":"341","author":"D Martinez Molina","year":"2013","unstructured":"Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013;341:84\u201387.","journal-title":"Science"},{"key":"775_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.snb.2014.12.121","volume":"210","author":"HY Zhai","year":"2015","unstructured":"Zhai HY, Liu ZP, Chen ZG, Liang ZX, Su ZH, Wang SM. A sensitive electrochemical sensor with sulfonated graphene sheets\/oxygen-functionalized multi-walled carbon nanotubes modified electrode for the detection of clenbuterol. Sens Actuators B-Chem. 2015;210:483\u201390.","journal-title":"Sens Actuators B-Chem"},{"key":"775_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/pr.112.005660","volume":"65","author":"HD Williams","year":"2013","unstructured":"Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65:315\u2013499.","journal-title":"Pharmacol Rev"},{"key":"775_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.tips.2014.02.004","volume":"35","author":"SC Wang","year":"2014","unstructured":"Wang SC. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014;35:178\u201386.","journal-title":"Trends Pharmacol Sci"},{"key":"775_CR26","first-page":"3472","volume":"15","author":"GJ Zhu","year":"2018","unstructured":"Zhu GJ, Song PP, Zhou H, Shen XH, Wang JG, Ma XF, et al. Role of epithelial-mesenchymal transition markers E-cadherin, N-cadherin, beta-catenin and ZEB2 in laryngeal squamous cell carcinoma. Oncol Lett. 2018;15:3472\u201381.","journal-title":"Oncol Lett"},{"key":"775_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2015.07.028","volume":"67","author":"JB Wu","year":"2015","unstructured":"Wu JB, Shi C, Chu GC, Xu Q, Zhang Y, Li Q, et al. Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for human brain tumor. Biomaterials. 2015;67:1\u201310.","journal-title":"Biomaterials"},{"key":"775_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/toxsci\/kfj141","volume":"91","author":"K Letschert","year":"2006","unstructured":"Letschert K, Faulstich H, Keller D, Keppler D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006;91:140\u20139.","journal-title":"Toxicol Sci"},{"key":"775_CR29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/ijms20030755","volume":"20","author":"T Tian","year":"2019","unstructured":"Tian T, Li X, Zhang J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci. 2019;20:755.","journal-title":"Int J Mol Sci"},{"key":"775_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1210\/me.2004-0305","volume":"19","author":"LP McMahon","year":"2005","unstructured":"McMahon LP, Yue W, Santen RJ, Lawrence JC Jr. Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. Mol Endocrinol. 2005;19:175\u201383.","journal-title":"Mol Endocrinol"},{"key":"775_CR31","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/cells8121597","volume":"8","author":"H Wang","year":"2019","unstructured":"Wang H, Liu Y, Wang D, Xu Y, Dong R, Yang Y, et al. The upstream pathway of mTOR-mediated autophagy in liver diseases. Cells. 2019;8:1597.","journal-title":"Cells"},{"key":"775_CR32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1517\/17460441003605098","volume":"5","author":"MJ Waring","year":"2010","unstructured":"Waring MJ. Lipophilicity in drug discovery. Expert Opin Drug Discov. 2010;5:235\u201348.","journal-title":"Expert Opin Drug Discov"},{"key":"775_CR33","doi-asserted-by":"crossref","unstructured":"Lindsley CW Lipophilicity. In: Stolerman I, Price L, editors. Encyclopedia of Psychopharmacology. Berlin; Heidelberg: Springer; 2014.","DOI":"10.1007\/978-3-642-27772-6_7015-1"},{"key":"775_CR34","doi-asserted-by":"publisher","first-page":"10114","DOI":"10.18632\/oncotarget.2464","volume":"5","author":"C Shi","year":"2014","unstructured":"Shi C, Wu JB, Chu GC, Li Q, Wang R, Zhang C, et al. Heptamethine carbocyanine dye-mediated near-infrared imaging of canine and human cancers through the HIF-1alpha\/OATPs signaling axis. Oncotarget. 2014;5:10114\u201326.","journal-title":"Oncotarget"},{"key":"775_CR35","unstructured":"Bruce A, Alexander J, Julian L, Martin R, Keith R, & Peter W. Transport into the cell from the plasma membrane: endocytosis. Molecular Biology of the Cell. 4th ed. New York: Garland Science; 2002."},{"key":"775_CR36","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.celrep.2018.06.110","volume":"24","author":"I Miller","year":"2018","unstructured":"Miller I, Min M, Yang C, Tian C, Gookin S, Carter D, et al. Ki67 is a graded rather than a binary marker of proliferation versus quiescence. Cell Rep. 2018;24:1105\u20131112.e5.","journal-title":"Cell Rep"},{"key":"775_CR37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1074\/jbc.271.2.611","volume":"271","author":"D Stapleton","year":"1996","unstructured":"Stapleton D, Mitchelhill KI, Gao G, Widmer J, Michell BJ, Teh T, et al. Mammalian AMP-activated protein kinase subfamily. J Biol Chem. 1996;271:611\u20134.","journal-title":"J Biol Chem"},{"key":"775_CR38","first-page":"69","volume":"41","author":"H Zhang","year":"2018","unstructured":"Zhang H, Liu B, Li T, Zhu Y, Luo G, Jiang Y, et al. AMPK activation serves a critical role in mitochondria quality control via modulating mitophagy in the heart under chronic hypoxia. Int J Mol Med. 2018;41:69\u201376.","journal-title":"Int J Mol Med"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00775-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00775-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00775-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T07:47:09Z","timestamp":1656920829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00775-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["775"],"URL":"https:\/\/doi.org\/10.1038\/s41401-021-00775-5","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"6 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}